Debra Richardson, MD
Gynecologic Oncology · Oklahoma City, OKNPI 1992784987
Payments from drug & device makers
Across 1,013 payments — averaging $7878.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3.6M
- AbbVie$1.3M
- Tesaro, Inc.$594K
- Aadi Bioscience, Inc.$582K
- Clovis Oncology, Inc.$316K
- Genmab U.S., Inc.$243K
- plus $1.4M from 24 others
Across 3 payments — averaging $413.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 230 | $3,607,675 |
| AbbVie | 19 | $1,264,801 |
| Tesaro, Inc. | 35 | $594,440 |
| Aadi Bioscience, Inc. | 15 | $581,674 |
| Clovis Oncology, Inc. | 34 | $316,181 |
| Genmab U.S., Inc. | 24 | $243,261 |
| Merck | 35 | $209,102 |
| AstraZeneca | 28 | $196,573 |
| Karyopharm Therapeutics Inc. | 63 | $184,263 |
| Deciphera Pharmaceuticals Inc. | 172 | $154,578 |
| Exelixis Inc. | 139 | $134,633 |
| Genentech, Inc. | 7 | $121,286 |
| F. Hoffmann-la Roche AG | 54 | $95,006 |
| Eli Lilly | 9 | $93,437 |
| Blueprint Medicines Corporation | 30 | $67,828 |
| Daiichi Sankyo Inc. | 64 | $41,272 |
| Roche Products Limited | 2 | $22,609 |
| Immunogen, Inc. | 15 | $11,123 |
| Ascendis Pharma Endocrinology Inc | 6 | $10,625 |
| Sanofi US Services Inc. | 5 | $10,394 |
| Foundation Medicine, Inc. | 5 | $5,275 |
| Eisai Inc. | 3 | $5,015 |
| Astrazeneca UK Limited | 1 | $3,500 |
| Hoffmann-la Roche Limited | 4 | $2,615 |
| Bayer | 2 | $1,616 |
| Genentech USA, Inc. | 6 | $1,369 |
| Seagen Inc. | 3 | $174 |
| Pfizer | 1 | $38 |
| Myriad Genetic Laboratories, Inc. | 1 | $36 |
| Astellas Pharma US Inc | 1 | $22 |
How this compares
$7,980,421 in reported general payments places this provider in the 95th percentile of 21 gynecologic oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Oklahoma City
- Robert MannelOklahoma City$5.8M
- Lauren DockeryOklahoma City$3M
- Christina WashingtonOklahoma City$1.6M
- Camille JacksonOklahoma City$886K
- Tara CastellanoOklahoma City$68K
- Joan WalkerOklahoma City$11K
- Elizabeth EvansOklahoma City$3K
- Ana ValenteOklahoma City$2K
- Nicole MinaltOklahoma City$2K
- Jacqueline BohnOklahoma City$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.